Literature DB >> 6861813

Pharmacokinetics of piroxicam in man.

D C Hobbs.   

Abstract

Piroxicam is a potent antiinflammatory agent currently in widespread use for the treatment of various inflammatory conditions of man. Following single oral doses of 10 to 100 mg, piroxicam is rapidly and fully absorbed, and eliminated with a mean plasma half life of about 45 hr. Mean peak concentrations are about 2 micrograms/ml after single 20 mg doses and about 6 micrograms/ml at steady state with 20 mg daily. Multiple peaking suggests enterohepatic recirculation of drug. In accord with expectations, steady state is achieved within 7 to 12 days with no appreciable accumulation thereafter. Due to the long plasma half life, once daily dosing provides continuous exposure to drug, with concentrations fluctuating less than twofold. Coadministration of aspirin reduces piroxicam levels by about 20 percent; antacids have no effect on piroxicam plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861813

Source DB:  PubMed          Journal:  Eur J Rheumatol Inflamm        ISSN: 0140-1610


  14 in total

1.  Comparative bioavailability of two different rectal preparations of piroxicam in man.

Authors:  S Benkö; G Grézal; E Nagy; I Klebovich
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

3.  Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions.

Authors:  X Deroubaix; A Stockis; A M Allemon; E Lebacq; D Acerbi; P Ventura
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Pharmacokinetic observations on piroxicam in young adult, middle-aged and elderly patients.

Authors:  A D Woolf; H J Rogers; I D Bradbrook; D Corless
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

5.  Plasma protein binding and interaction studies with piroxicam.

Authors:  Z Trnavská; K Trnavský
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-08       Impact factor: 3.000

6.  Single-dose and steady-state pharmacokinetics of piroxicam in elderly vs young adults.

Authors:  A Darragh; A J Gordon; H O'Byrne; D Hobbs; E Casey
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  The influence of cholestyramine on the elimination of tenoxicam and piroxicam.

Authors:  T W Guentert; R Defoin; H Mosberg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 8.  Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

9.  Influence of cyclodextrin complexation with NSAIDs on NSAID/cold stress-induced gastric ulceration in rats.

Authors:  Ibrahim A Alsarra; Mahrous O Ahmed; Fars K Alanazi; Kamal Eldin Hussein Eltahir; Abdulmalik M Alsheikh; Steven H Neau
Journal:  Int J Med Sci       Date:  2010-07-05       Impact factor: 3.738

10.  Binding of piroxicam to synovial fluid and plasma proteins in patients with rheumatoid arthritis.

Authors:  Z Trnavská; K Trnavský; D Zlnay
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.